The company currently employs more than 850 employees worldwide. The Copenhagen facility will add a Single-use Bioreactor (SUB) 6Pack suite, consisting of six 2000L production bioreactors and a 2000L seed train.

The innovative platform utilizes robust procedures and reliable raw materials, including chemically defined media, adapted Chinese hamster ovary (CHO) cells, and CHEF1 expression plasmids, to produce high levels of recombinant protein in rapid timeframes. Head Office. Production Base; AGC Biologics, Inc. Copenhagen plant.

The addition of this proprietary bioreactor configuration will enable more flexible, […] AGC Biologics offers deep industry expertise and unique customized services for the scale-up and cGMP manufacture of protein-based therapeutics, from pre-clinical to commercial mammalian and microbial … The innovative platform utilizes robust procedures and reliable raw materials, including chemically defined media, adapted Chinese hamster ovary (CHO) cells, and CHEF1 expression plasmids, to produce high levels of recombinant protein in rapid timeframes. AGC Chemicals Company. Biopharmaceutical CMO (Contract Manufacturing Organization) Czernyring 22 69115 Heidelberg, Germany TEL: +49 (0) 6221-90260 FAX: +49 (0) 6221-902690. AGC Biologics announced that as part of its global expansion strategy, the company is increasing manufacturing capacity at its Copenhagen, Denmark facility. AGC Biologics’ proprietary CHEF1 ® Expression System accelerates development of cell lines for cGMP biologics production. AGC Biologics’ proprietary CHEF1 ® Expression System accelerates development of cell lines for cGMP biologics production. AGC Biologics partners with Novavax to produce NVX-CoV2373 component SEATTLE, June 3, 2020 /PRNewswire/ -- AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing AGC Biologics is rapidly expanding its customer portfolio, including a higher ratio of late phase and commercial projects, as well as advancing current projects into the commercial phase. SEATTLE- - AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced that it will partner with Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, on large-scale GMP production of … AGC Biologics noted it is the product of the convergence and integration of Asahi Glass Company (AGC) Bioscience, Biomeva GmbH, and CMC Biologics. by Dan Stanton Monday, September 16, 2019 12:23 am.

This addition to their facility network will enable AGC Biologics to support a wider range of commercial demand.